Literature DB >> 17897389

Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus.

M C Collado1, J Meriluoto, S Salminen.   

Abstract

AIMS: The aims of this study present were to assess and to evaluate in vitro the abilities of commercial probiotic strains derived from fermented milk products and related sources currently marketed in European countries, to inhibit, compete and displace the adhesion of selected potential pathogens to immobilized human mucus. METHODS AND
RESULTS: The adhesion was assessed by measuring the radioactivity of bacteria adhered to the human mucus. We tested 12 probiotic strains against eight selected pathogens. All strains tested were able to adhere to mucus. All probiotic strains tested were able to inhibit and displace (P<0.05) the adhesion of Bacteroides, Clostridium, Staphylococcus and Enterobacter. In addition, the abilities to inhibit and to displace adhered pathogens depended on both the probiotic and the pathogen strains tested suggesting that several complementary mechanisms are implied in the processes.
CONCLUSIONS: Our results indicate the need for a case-by-case assessment in order to select strains with the ability to inhibit or displace a specific pathogen. Probiotics could be useful to correct deviations observed in intestinal microbiota associated with specific diseases and also, to prevent pathogen infections. SIGNIFICANCE AND IMPACT OF THE STUDY: The competitive exclusion properties of probiotics as well as their ability to displace and inhibit pathogens are the most importance for therapeutic manipulation of the enteric microbiota. The application of such strategies could contribute to expand the beneficial properties on human health against pathogen infection.

Entities:  

Mesh:

Year:  2007        PMID: 17897389     DOI: 10.1111/j.1472-765X.2007.02212.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  65 in total

1.  Microbial Metabolites as Molecular Mediators of Host-Microbe Symbiosis in Colorectal Cancer.

Authors:  N P Hyland; A Houston; J M Keane; S A Joyce; C G M Gahan
Journal:  Results Probl Cell Differ       Date:  2020

2.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

3.  Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse.

Authors:  C A Danilo; E Constantopoulos; L A McKee; H Chen; J A Regan; Y Lipovka; S Lahtinen; L K Stenman; T-V V Nguyen; K P Doyle; M J Slepian; Z I Khalpey; J P Konhilas
Journal:  Benef Microbes       Date:  2017-04-14       Impact factor: 4.205

Review 4.  Probiotics for the treatment of inflammatory bowel disease.

Authors:  Ganesh R Veerappan; John Betteridge; Patrick E Young
Journal:  Curr Gastroenterol Rep       Date:  2012-08

5.  Carbohydrate-binding specificities of potential probiotic Lactobacillus strains in porcine jejunal (IPEC-J2) cells and porcine mucin.

Authors:  Valerie Diane Valeriano; Bernadette B Bagon; Marilen P Balolong; Dae-Kyung Kang
Journal:  J Microbiol       Date:  2016-06-28       Impact factor: 3.422

6.  Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation.

Authors:  Peera Hemarajata; James Versalovic
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

7.  Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents.

Authors:  Sampo J Lahtinen; Liisa Tammela; Jaakko Korpela; Riikka Parhiala; Henri Ahokoski; Hannu Mykkänen; Seppo J Salminen
Journal:  Age (Dordr)       Date:  2008-11-28

Review 8.  How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  J Biol Chem       Date:  2015-02-03       Impact factor: 5.157

9.  Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.

Authors:  Sylvia Kleta; Marcel Nordhoff; Karsten Tedin; Lothar H Wieler; Rafal Kolenda; Sibylle Oswald; Tobias A Oelschlaeger; Wilfried Bleiss; Peter Schierack
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

10.  In vitro screening and in vivo colonization pilot model of Lactobacillus plantarum LP5 and Campylobacter coli DSPV 458 in mice.

Authors:  M J Ruiz; M V Zbrun; M L Signorini; J A Zimmermann; L P Soto; M R Rosmini; L S Frizzo
Journal:  Arch Microbiol       Date:  2021-06-01       Impact factor: 2.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.